NCT06230302

Efficacy and Safety of Kefir Whey Postbiotics

12 Weeks, Randomized, Double-blind, Placebo-controlled Trial on the Efficacy and Safety of Kefir Whey Postbiotics
Hanyang University·ClinicalTrials.gov·dietary supplementEnrolling by invitation
View on ClinicalTrials.gov
Study focus
Disease/Condition
Sarcopenia
Drug/Device/Intervention
Whey postbiotics derived from kefir lactic acid bacteria
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Hanyang University
Location
Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
Dec 26, 2023
End date
Jul 31, 2024
Enrollment
60 participants
Primary outcome

Grip strength test for both hands,Dual energy xray absorptiometry

Summary

Research staff conduct screening tests only on applicants who provide written consent and
 select research subjects who meet the selection criteria. Study subjects will visit for the
 first time within 4 weeks from the screening visit to reexamine the suitability of the study
 subject selection/exclusion criteria and then be enrolled in the human application test. The
 participants will be randomly assigned to the kefir lactic acid bacteria-derived whey
 post-biotics group and the placebo group for the first time. Complete the baseline evaluation
 by the date of visit. Afterwards, the participants will consume whey postbiotics derived from
 kefir lactic acid bacteria and a placebo product twice a day, 3g per time, for 12 weeks, and
 visit the institution a total of four times to perform a grip strength test, DXA. This survey
 will be conducted at Hanyang University Hospital. Research staff may conduct follow-up
 observations of study subjects as needed after final consumption of the kefir lactic acid
 bacteria-derived whey postbiotic group and placebo products or after early termination.

ICD-10 classifications
Kaposi sarcomaHerniaTaeniasisTaenia saginata taeniasisDiaphragmatic hernia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06230302
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06230302 through Pure Global AI's free database. This phase not specified trial is sponsored by Hanyang University and is currently Enrolling by invitation. The study focuses on Sarcopenia. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.